Compare · OCDX vs VRAX
OCDX vs VRAX
Side-by-side comparison of Ortho Clinical Diagnostics Holdings plc (OCDX) and Virax Biolabs Group Limited (VRAX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OCDX and VRAX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- OCDX carries a market cap of $4.08B.
- VRAX has hit the wire 3 times in the past 4 weeks while OCDX has been quiet.
- OCDX has more recent analyst coverage (8 ratings vs 1 for VRAX).
- Company
- Ortho Clinical Diagnostics Holdings plc
- Virax Biolabs Group Limited
- Price
- $17.64+0.46%
- $0.16+0.50%
- Market cap
- $4.08B
- -
- 1M return
- -
- -13.45%
- 1Y return
- -
- -83.38%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2022
- News (4w)
- 0
- 3
- Recent ratings
- 8
- 1
Ortho Clinical Diagnostics Holdings plc
Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company also engages in contract manufacturing activities; and provides orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. The company was founded in 1939 and is headquartered in Raritan, New Jersey.
Virax Biolabs Group Limited
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company offers rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, and individual consumers. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. The company was incorporated in 2021 and is based in London, the United Kingdom.
Latest OCDX
- SEC Form 15-12B filed by Ortho Clinical Diagnostics Holdings plc
- SEC Form 4: Iskra Michael S. returned 150,000 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Busky Joseph M
- SEC Form 4: Schlesinger Michael A. returned 87,637 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Palaniappan Chockalingam
- SEC Form 4: Yates Robert Clifton returned 323,880 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Smith Christopher M returned 367,360 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Dilsaver Evelyn S returned 5,200 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Mac Mahon Thomas P returned 141,853 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Labrum Ronald K returned 109,985 units of Ordinary Shares to the company, closing all direct ownership in the company
Latest VRAX
- SEC Form 6-K filed by Virax Biolabs Group Limited
- Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders
- SEC Form 6-K filed by Virax Biolabs Group Limited
- SEC Form 3 filed by new insider Haight Nelson M
- Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
- SEC Form 3 filed by new insider Mccracken Nigel William
- SEC Form 6-K filed by Virax Biolabs Group Limited
- SEC Form 3 filed by new insider Foster James Alexander Cunliffe
- SEC Form 3 filed by new insider Norton Evan Michael
- SEC Form 3 filed by new insider Davis Jason